课题基金 / 基金详情

High Throughput Modular Microfluidic Systems for Drug Discovery/Development

High Throughput Modular Microfluidic Systems for Drug Discovery/Development
用于药物发现/开发的高通量模块化微流体系统
批准号:
7900284
负责人:
Steven Allan Soper
金额:
$11.84万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-08-01 至 2011-07-31

项目摘要

项目成果

Steven Allan Soper的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):BioMEMS(生物微机电系统)被视为在药物发现等领域执行许多不同的基于生物的分析的下一代平台,因为它们具有提供改进性能和低分析成本的潜力。然而,到目前为止,在高通量筛选(HTS)中使用BioMEMS的报告中,尚未实现吞吐量和成本的潜在改进。本研究的重点是开发新的高度集成的聚合物BioMEMS平台,以实现平行红外荧光法筛选候选药物文库的优势。为了证明该技术的有效性,L1内切酶(L1- en)的抑制剂将被筛选。L1-EN通过TTTT'AA共识序列诱导双链断裂,并可能导致导致细胞衰老、癌症形成或进展的遗传损伤。因此,目前尚无L1-EN抑制剂的发现,可能在减少癌症治疗或衰老某些方面的遗传不稳定性方面发挥重要作用。将要开发的平台有几种使能技术,可以通过显著减少设备需求和最大限度地降低消耗性成本,将HTS能力传播到更广泛的药物发现界。该系统将由大量的流体处理器(96-192)组成,配置在使用微复制生产的6英寸聚合物晶圆上。每个流体处理器将由(1)相互连接的芯片组成,将化合物直接从滴度板送入主处理器晶片;(2)加速试剂混合的微型混合器;(3)固定化靶物的高表面积生物反应器;(4)采用多通道荧光检测技术对流体流动细胞进行分组识别电位导联。L1-EN的底物将用新的近红外荧光酞菁染料进行双标记,这种染料具有高灵敏度和低本底。通过将一组紧密间隔的通道成像到CCD相机上,可以从流体流动细胞中读出平行荧光。仿真和建模将指导选择适当的读出格式和光学配置。在其最终格式中,该系统将能够在24小时内筛选-190,000种候选药物。流体处理将通过微流体完成,机器人干预最少,因为只需要一个样品转移步骤就可以将候选药物加载到系统中。
英文摘要
DESCRIPTION (provided by applicant): BioMEMS (Biological-MicroElectroMechanical Systems) are seen as the next generation platform for performing many different biologically-based assays in areas such as drug discovery, due to their potential for providing improved performance and low assay cost. However, in reports to date of BioMEMS used in high throughput screening (HTS), the potential improvements in throughput and costs have yet to be realized. This research focuses on developing new highly integrated polymer BioMEMS platforms to achieve advantages in the screening of libraries of drug candidates using parallelized infrared fluorescence assays. As a demonstration of the efficacy of the technology, inhibitors of L1 endonuclease (L1-EN) will be screened. L1-EN induces double-strand breaks via a TTTT'AA consensus sequence and can contribute to genetic damage responsible for cellular aging, cancer formation or progression. Therefore, discovery of inhibitors of L1-EN, of which there is currently none, could play an important role in minimizing genetic instability during cancer therapies or certain aspects of aging. The platforms to be developed have several enabling technologies that will allow the dissemination of HTS capabilities into the broader drug-discovery community by significantly reducing equipment demands and minimizing consumable costs. The system will consist of a large number of fluidic processors (96-192) configured on a 6" polymer wafer produced using micro- replication. Each fluidic processor will consist of (1) interconnected chip(s) to feed compounds directly from titer plates to the main processor wafer; (2) micromixer that speeds reagent mixing; (3) high surface area bioreactor in which the target is immobilized; and (4) grouped fluidic flow-cells for identifying potential leads using multi-channel fluorescence detection. A substrate of L1-EN will be dual-labeled with new, near-IR fluorescent phthalocyanine dyes, which provide high sensitivity and low background. Parallel fluorescence readout from the fluidic flow cells will be carried out by imaging a group of tightly spaced channels onto a CCD camera. Simulation and modeling will guide the selection of an appropriate readout format and optical configuration. In its finished format, the system will be able to screen -190,000 drug candidates in 24 hr. Fluid handling will be accomplished via microfluidics with minimal robotic intervention, as only a single sample transfer step is required to load the system with drug candidates.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Using integrated omics to identify dysfunctional genetic mechanisms influencing schizophrenia and sleep disturbances
Detection of MRD in TNBC Through Multi-Platform Molecular Biomarker Analysis
Biomedical Engineering Core
Biomedical Engineering Core
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
  • 批准号:
    2021JJ40433
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    孙磊
  • 依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
  • 批准号:
    32001603
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    段真珍
  • 依托单位:
AREA国际经济模型的移植.改进和应用
  • 批准号:
    18870435
  • 项目类别:
    面上项目
  • 资助金额:
    2.0万元
  • 批准年份:
    1988
  • 负责人:
    史树中
  • 依托单位: